The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.

Drug Category : Array
Conference Category : Array
Lead Author : Locatelli S, Carlo-Stella C, et al.
Published Date : 10/12/2013
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2020/05/Locatelli-ASH2013Poster1835.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top